COVID-19：吸入型イベルメクチンの研究：ブルックデール大学病院（動画）：
Study Inhaled Form Ivermectin for COVID-19：
研究吸入形式伊维菌素的COVID-19
COVID-19：吸入型イベルメクチンの研究
NYブルックデール大学：
病院医療センターの医師グループ。
最近、彼らの論文が、査読ジャーナルCureusに掲載されました。
研究チームは、COVID-19患者に対し、安全で効果的な治療法を提案しています。
豪モナッシュ大学での研究：
SARS-CoV-2に対し「濃縮された吸入型イベルメクチン投与が、効果的であり、更に研究する必要がある」とも指摘しています。
Although not documented, which isn’t totally true as TrialSite has chronicled several observational studies, and even one randomized controlled trial, the authors choose to ignore these except for the ICON study in Broward County.
Regardless, they suggest that the anthelminthic drug may have broad-spectrum antiviral properties, which could make it effective against viral infections such as SARS-CoV-2.
They emphasize a need to study ivermectin in an inhaled form and although TrialSite suggests these physicians could have dug a little deeper into studies in the developing world such as in
- Bangladesh,
- Argentina or for that matter,
- Egypt and Iraq,
they are on the right side of history here suggesting research proceed.